乌司他丁在原发性肝癌介入治疗中保护肝功能的临床观察  

Ulinastatin in the Protection of Liver Function in the Interventional Therapy of Primary Hepatic Carcinoma:Clinical Observation

作　　者：黄冬[1] 马晓鹂[1] 

机构地区：[1]广东医学院附属医院药学部,湛江市524001

出　　处：《中国药房》2007年第17期1336-1337,共2页China Pharmacy

摘　　要：目的:探讨乌司他丁在原发性肝癌介入治疗中的护肝作用。方法:将110例原发性肝癌患者随机分为治疗组与对照组。对照组给予常规药物治疗,治疗组在对照组治疗基础上加用乌司他丁治疗,监测2组肝功能变化及腹水生成情况。结果:介入治疗第3天治疗组丙氨酸氨基转移酶、天门冬酸氨基转移酶、总胆红素上升幅度均较对照组低(P<0·05);治疗第7天治疗组丙氨酸氨基转移酶、天门冬酸氨基转移酶显著低于对照组,总蛋白显著高于对照组(P<0·05)。2组腹水生成率无显著性差异(P>0·05)。结论:乌司他丁在原发性肝癌介入治疗中可产生显著的护肝作用。OBJECTIVE： To discuss the effect of ulinastatin（UTI） in the protection of liver function in the interventional therapy of primary liver carcinoma.METHODS：A total of 110 patients with primary hepatic carcinoma were randomly assigned to receive routine therapy（control group） or routine therapy plus UTT（trial group）, with liver functional changes and ascites formation of two groups monitored.RESULTS： On day 3 after interventional therapy, increases of ALT, AST and TBil in the trial group were lower than in the control group（P〈0.05）,but on day 7,the ALT,AST and TBil were significantly lower and TP was significantly higher as compared with control group（P 〈 0.05）.There was no significant difference in ascites formation rate between two groups（P〉0.05） .CONCLUSION：UTI showed a satisfactory effect in the protection of liver function in the interventional therapy for patients with primary hepatic carcinoma.

关 键 词：原发性肝癌 乌司他丁 介入治疗 

分 类 号：R969.4[医药卫生—药理学] R975.5[医药卫生—药学]